Abstract
The effect of 2-chloroadenosine (2CA), an adenosine receptor agonist, on the activation status of mouse natural killer (NK) cells was determined. Splenic lymphocytes incubated with 2CA exocytosed an NK cell-associated granzyme with N alpha-CBZ-L-lysine thiobenzyl ester (BLT) esterase activity in a dose- and time-dependent manner. Selective depletion of NK cells by anti-asialoGM1 antibody plus complement pretreatment confirmed that NK cells were the source of the BLT esterase activity. 2CA-induced granule exocytosis was not reduced in the presence of the nucleoside uptake blockers NBTI, dilazep, or dipyridamole, indicating the involvement of an extracellular receptor. However, adenosine or other A1, A2, or A3 cell-surface adenosine receptor agonists failed to trigger the exocytotic process. Furthermore, the nonselective adenosine receptor antagonist theophylline, as well as the selective A1 receptor antagonist DPCPX and the selective A2 receptor antagonist DMPX, did not interfere with 2CA-induced BLT esterase secretion. These data suggest that 2CA acts on NK cells via a novel (non-A1/A2/A3) cell-surface receptor. Genistein, a protein tyrosine kinase inhibitor, and calphostin C, a protein kinase C inhibitor, both interfered with ...Continue Reading
References
Jun 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·L J Wysocki, V L Sato
Mar 1, 1979·Analytical Biochemistry·G D Green, E Shaw
Aug 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·Q Y ZhouO Civelli
Sep 9, 1992·International Journal of Cancer. Journal International Du Cancer·B Y YungE S Lee
Dec 1, 1992·The Journal of Experimental Medicine·L ShiA H Greenberg
Jan 1, 1992·Advances in Immunology·H YagitaK Okumura
Apr 1, 1992·European Journal of Immunology·F VelottiA Santoni
May 1, 1992·Cellular Immunology·R Krishnaraj
Jan 1, 1991·Life Sciences·Y ZhangW W Lautt
Jul 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·K J EinspahrP J Leibson
Jan 1, 1990·Annual Review of Physiology·B D Gomperts
Jan 1, 1990·Journal of Leukocyte Biology·E A AtkinsonA H Greenberg
Nov 1, 1990·Biochemical Pharmacology·G MaroneV Casolaro
Dec 1, 1990·The Biochemical Journal·M M Whalen, A D Bankhurst
Mar 28, 1986·Cell·J D YoungZ A Cohn
Mar 15, 1989·Biochemical and Biophysical Research Communications·E KobayashiT Tamaoki
Jan 1, 1989·Advances in Immunology·G Trinchieri
Dec 15, 1986·Biochemical and Biophysical Research Communications·P A Baeuerle, W B Huttner
May 23, 1988·FEBS Letters·S ClaeyssensA Lavoinne
Sep 15, 1985·Biochemical Pharmacology·S M JarvisA S Ng
Jul 1, 1982·British Journal of Pharmacology·C M Brown, M G Collis
Mar 1, 1984·Cell·A G Gilman
Mar 1, 1980·European Journal of Immunology·M KasaiT Tada
Nov 1, 1995·European Journal of Immunology·J CarracedoG Kroemer
Sep 8, 1995·Cell·D H Raulet, W Held
Nov 1, 1993·The Journal of Experimental Medicine·F PaliogianniD T Boumpas
Apr 1, 1995·Immunology Today·M J Smyth, J A Trapani
Sep 1, 1994·The Journal of Experimental Medicine·R RamírezG Kroemer
Apr 1, 1993·Journal of Leukocyte Biology·T J SayersR H Wiltrout
Citations
Dec 2, 2009·Modern Rheumatology·Edwin S L Chan, Bruce N Cronstein
Jul 16, 2008·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Balázs CsókaGyörgy Haskó
Dec 28, 2007·Journal of Leukocyte Biology·György Haskó, Pál Pacher
Sep 4, 2015·Immunology·Felipe Flores-SantibáñezDaniela Sauma
Jun 21, 2006·Pharmacology & Therapeutics·M J L BoursP C Dagnelie
May 25, 2016·Neuroscience·Yumei LiuHulun Li
Nov 15, 2013·Nature Reviews. Cancer·Luca AntonioliGyörgy Haskó